Johnson & Johnson’s IMAAVY Demonstrates Durable Disease Control in Myasthenia Gravis

Johnson & Johnson (NYSE:JNJ) has reported new data from its Phase 3 Vivacity-MG3 trial showing that its therapy IMAAVY ...

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...

Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026

Pre-randomization Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) set-up data from the MODERATO II randomized, prospective, ...
Medical Dialogues

Biofield Therapy Shows Potential to Slow Pancreatic Cancer Progression, suggests research

A preclinical study published in the journal of Cancer Medicine suggested that biofield therapy (BT), which is a touch-based ...
TMCnet

CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors

CREATE Medicines, Inc., ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune cell programming, today ...
Medindia

How 3D Minibrains are Redefining Rett Syndrome Therapy

Using brain organoids, researchers showed that specific genetic mutations in Rett syndrome cause distinct brain network ...

PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma

Individual experimental treatment attempt at Hopp Children’s Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a ...
PharmiWeb

Genialis Supermodel Predicts Patient Response to HER2-Targeted Therapy Enhertu

At AACR 2026, the Genialis™ Supermodel–powered RNA survival model outperforms standard of care in real-world clinical data, establishing a scalable biomarker framework for ADC drug developmentBOSTON-- ...
Medscape

Managing Care When Gender-Affirming Therapy Is Limited

As access to gender-affirming care for minors narrows, clinicians are adapting — using nonhormonal options, stronger mental ...

Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or ...

The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of ...
The Manila Times

IMAAVY® (nipocalimab) shows over two years of sustained disease control in a broad population with generalised myasthenia gravis (gMG)

Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ ...